CD274 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain CD274 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (3 open) [4].

CD274 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD274 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for bladder squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and bladder squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for bronchioloalveolar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and bronchioloalveolar carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for cervical clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and cervical clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for esophageal undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and esophageal undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for gestational trophoblastic tumor, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and gestational trophoblastic tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for lung sarcomatoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and lung sarcomatoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for malignant giant cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and malignant giant cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for malignant odontogenic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and malignant odontogenic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for mucinous tubular and spindle cell carcinoma of the kidney, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and mucinous tubular and spindle cell carcinoma of the kidney as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for ovarian small cell carcinoma, hypercalcemic type, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and ovarian small cell carcinoma, hypercalcemic type as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pecoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for pancreatic acinar cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pancreatic acinar cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for pancreatic cystadenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pancreatic cystadenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for pancreatic serous cystadenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pancreatic serous cystadenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and penile carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for prostate small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and prostate small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for prostate squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and prostate squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for renal pelvis squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and renal pelvis squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for small intestinal undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and small intestinal undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for undifferentiated gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and undifferentiated gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for ureter squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and ureter squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD274 is an inclusion criterion in 1 clinical trial for urethral squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and urethral squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].